Holen Sie sich die Stockscreener-App
1.20
4.00%
-0.05
Handel nachbörslich:
1.21
0.01
+0.83%
Schlusskurs vom Vortag:
$1.25
Offen:
$1.27
24-Stunden-Volumen:
918.43K
Relative Volume:
1.75
Marktkapitalisierung:
$73.00M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-24.25M
KGV:
-1.7657
EPS:
-0.6796
Netto-Cashflow:
$-19.95M
1W Leistung:
-8.40%
1M Leistung:
-14.89%
6M Leistung:
-18.37%
1J Leistung:
-23.57%
1-Tages-Spanne:
$1.20
$1.33
1-Wochen-Bereich:
$1.20
$1.38
52-Wochen-Spanne:
$0.87
$3.19
MAIA Biotechnology Inc Stock (MAIA) Company Profile
Firmenname
MAIA Biotechnology Inc
Sektor
Branche
Telefon
312 416 8592
Adresse
444 West Lake Street, Suite 1700, Chicago
Compare MAIA vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MAIA
MAIA Biotechnology Inc
|
1.20 | 73.00M | 0 | -24.25M | -19.95M | -0.6796 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
MAIA Biotechnology Inc Aktie (MAIA) Neueste Nachrichten
MAIA Biotechnology reports 90.5% disease control rate in NSCLC trial - scanx.trade
MAIA Biotechnology doses first US patient in Phase 2 lung cancer trial - scanx.trade
MAIA Biotechnology files $150 million mixed shelf offering with SEC - scanx.trade
MAIA Biotechnology files resale prospectus for 751,879 shares - scanx.trade
Form S-3 Maia Biotechnology Inc For: 25 September By Investing.com - Investing.com Nigeria
MAIA Biotechnology, Inc. (MAIA) Stock Price, News, Quote & History - Yahoo! Finance Canada
MAIA Biotechnology expands pivotal Phase 3 THIO-104 NSCLC trial into Spain and Portugal - Dealroom
MAIA Biotechnology Announces Spain and Portugal Regulatory Approvals for THIO-104 Phase 3 NSCLC Trial - quiverquant.com
About 30,000 new lung cancer cases occur yearly in Spain and Portugal; a trial has approval to screen patients there. - Stock Titan
MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer - Yahoo Finance
A $2.3 million National Institutes of Health grant funds a cancer trial. MAIA doses its first U.S. patient. - Stock Titan
MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial - Yahoo Finance
MAIA Biotechnology Announces Insider Share Purchases by Board Member and CEO Amid Positive Phase 3 and Phase 2 Data Updates - Quiver Quantitative
Maia Biotechnology CEO Vlad Vitoc buys $100,010 in company stock - Investing.com
Maia Biotechnology CEO Vlad Vitoc buys $100,010 in company stock By Investing.com - Investing.com UK
MAIA Biotechnology (NYSE: MAIA) CEO adds 73,000 shares at $1.37 - Stock Titan
Maia Biotechnology director buys $49,516 in company shares By Investing.com - Investing.com South Africa
Maia Biotechnology director buys $49,516 in company shares - Investing.com
MAIA Biotechnology Delivers Oral and Poster Presentations - GlobeNewswire
MAIA's next-generation cancer candidates showed more activity in lab and animal tests - Stock Titan
MAIA Biotechnology Inc. (MAIA) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
New Form 4 - Moomoo
MAIA Biotechnology, Inc. SEC Filing (Aug 31, 2026) - Stock Titan
MAIA Biotechnology Inc. (MAIA) Key Financial Ratios – Valuation, Profitability & More - Value Research
MAIA Biotechnology Inc. (MAIA) Peer Comparison – Compare with Others - Value Research
Maia Biotechnology director Guerrero buys $2,386 in common stock - Investing.com
Price to earnings forward of MAIA Biotechnology, Inc. – AMEX:MAIA - TradingView
MAIA (MAIA) Latest: Declines 0.07% to $1.38 in the Latest Session; Chart Watch: the Session Ends Within the Reported Technical Boundaries at the CloseDouble Top - vinanet.vn
MAIA Biotechnology Q3 EPS Forecast Lowered by Diamond Equity - MarketBeat
MAIA (MAIA) Q2 2026 Results: EPS Does Not Reach the Reported Estimate on the Day; Post-Earnings: The Stock Records a 3.28% Increase in the Current UpdatePositive Surprise Momentum - vinanet.vn
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) - Yahoo Finance
Centric Wealth Management Takes Position in MAIA Biotechnology, Inc. $MAIA - MarketBeat
Solas Capital discloses 4.9% MAIA Biotechnology (MAIA) stake in Schedule 13G/A - Stock Titan
MAIA Q2 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue Biotech Challenges - Vinanet
Maia Biotechnology Inc (MAIA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MAIA Biotechnology Q2 Results: EPS misses estimates - scanx.trade
MAIA Biotechnology 6M 2026: Net loss $(14.31M), Diluted EPS $(0.27) — 10-Q Summary - TradingView
MAIA Biotechnology (MAIA) Projected to Release Earnings on Monday - MarketBeat
MAIA Biotechnology Q1 2026 Earnings: EPS Beats Estimates, No Revenue ReportedMargin Compression Risk - dars.gov.et
MAIA Biotechnology, Inc. Revenue Breakdown – AMEX:MAIA - TradingView
MAIA|Maia Biotechnology Inc|Price:1.255|Chg%:+0.005 - TradingKey
Maia Biotechnology Inc (MAIA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com
Maia Biotechnology Inc (MAIA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Maia Biotechnology Inc (MAIA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Maia Biotechnology Inc (MAIA) Institutional Confidence - TradingKey
MAIA|Maia Biotechnology Inc|Price:1.240|Chg%:-0.040 - TradingKey
Maia Biotechnology Inc (MAIA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Maia Biotechnology Inc (MAIA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MAIA Biotechnology (MAIA) Gains 3.23% as Shares Push Toward $1.28 Resistance LevelAnalyst Upgrade Stocks - vinanet.vn
Finanzdaten der MAIA Biotechnology Inc-Aktie (MAIA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
Kapitalisierung:
|
Volumen (24h):